Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More
ZYDUS LIFESCIENCES ACTAVIS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ZYDUS LIFESCIENCES Mar-23 |
ACTAVIS Dec-18 |
ZYDUS LIFESCIENCES/ ACTAVIS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 495 | 16,159 | - | |
Low | Rs | 319 | 10,840 | - | |
Sales per share (Unadj.) | Rs | 170.3 | 3,963.8 | - | |
Earnings per share (Unadj.) | Rs | 19.8 | -1,276.8 | - | |
Cash flow per share (Unadj.) | Rs | 26.9 | 417.7 | - | |
Dividends per share (Unadj.) | Rs | 6.00 | 0 | - | |
Avg Dividend yield | % | 1.5 | 0 | - | |
Book value per share (Unadj.) | Rs | 173.0 | 16,349.0 | - | |
Shares outstanding (eoy) | m | 1,012.20 | 332.60 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 2.4 | 3.4 | 70.2% | |
Avg P/E ratio | x | 20.6 | -10.6 | -194.7% | |
P/CF ratio (eoy) | x | 15.1 | 32.3 | 46.8% | |
Price / Book Value ratio | x | 2.4 | 0.8 | 285.0% | |
Dividend payout | % | 30.3 | 0 | - | |
Avg Mkt Cap | Rs m | 412,144 | 4,489,898 | 9.2% | |
No. of employees | `000 | NA | 16.9 | 0.0% | |
Total wages/salary | Rs m | 24,564 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 78,010.2 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | -25,127.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 172,374 | 1,318,372 | 13.1% | |
Other income | Rs m | 4,746 | 25,212 | 18.8% | |
Total revenues | Rs m | 177,120 | 1,343,584 | 13.2% | |
Gross profit | Rs m | 29,677 | 34,548 | 85.9% | |
Depreciation | Rs m | 7,227 | 563,576 | 1.3% | |
Interest | Rs m | 1,299 | 76,078 | 1.7% | |
Profit before tax | Rs m | 25,897 | -579,893 | -4.5% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 147,896 | 0.0% | |
Tax | Rs m | 5,878 | -7,349 | -80.0% | |
Profit after tax | Rs m | 20,019 | -424,648 | -4.7% | |
Gross profit margin | % | 17.2 | 2.6 | 657.0% | |
Effective tax rate | % | 22.7 | 1.3 | 1,791.0% | |
Net profit margin | % | 11.6 | -32.2 | -36.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 100,082 | 540,727 | 18.5% | |
Current liabilities | Rs m | 55,267 | 478,345 | 11.6% | |
Net working cap to sales | % | 26.0 | 4.7 | 549.5% | |
Current ratio | x | 1.8 | 1.1 | 160.2% | |
Inventory Days | Days | 50 | 20 | 256.8% | |
Debtors Days | Days | 94 | 66 | 141.0% | |
Net fixed assets | Rs m | 144,776 | 149,232 | 97.0% | |
Share capital | Rs m | 1,012 | 0 | - | |
Net worth | Rs m | 175,158 | 5,437,670 | 3.2% | |
Long term debt | Rs m | 0 | 1,914,801 | 0.0% | |
Total assets | Rs m | 244,940 | 8,500,316 | 2.9% | |
Interest coverage | x | 20.9 | -6.6 | -316.1% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 0.7 | 0.2 | 453.7% | |
Return on assets | % | 8.7 | -4.1 | -212.2% | |
Return on equity | % | 11.4 | -7.8 | -146.4% | |
Return on capital | % | 15.5 | -4.8 | -320.7% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 26,888 | 471,005 | 5.7% | |
From Investments | Rs m | 11,712 | 258,756 | 4.5% | |
From Financial Activity | Rs m | -44,004 | -808,385 | 5.4% | |
Net Cashflow | Rs m | -5,338 | -78,232 | 6.8% |
Compare ZYDUS LIFESCIENCES With: MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare ZYDUS LIFESCIENCES With: IND SWIFT LA PIRAMAL PHARMA KREBS BIOCHEMICALS SHILPA MEDICARE WINDLAS BIOTECH
It was indeed a volatile trading session for Indian share markets yesterday.